Overview

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Radiant Research